Rob Hershberg, HilleVax CEO
September 8, 2021 08:00 AM EDTUpdated 08:59 AM
Financing

One of Tachi's new­ly born lega­cy biotechs rais­es $135M and en­lists an A-list board to ad­vance late-stage vac­cine

Paul Schloesser

Associate Editor

Tachi is gone, but his lega­cy biotechs are con­tin­u­ing to make news.

This morn­ing it’s the new­ly born Hill­e­Vax — a cre­ation of Take­da and Fra­zier …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times